Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Status:
Active, not recruiting

Trial end date:
2027-02-16

Target enrollment:

Participant gender:

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Phase 3

Pfizer